Danaher Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Rainer Blair
- Full Time Employees
- 61,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 2200 Pennsylvania Avenue, NW Washington DC United States of America 20037-1701
- IPO Date
- Dec 29, 1978
- CIK
- 0000313616
- Website
- danaher.com
- Similar Companies
- Business
- Danaher Corporation (NYSE: DHR), founded in 1984 and headquartered in Washington, D.C., operates as a leading global science and technology innovator focused on life sciences and diagnostics. The company conducts business through three primary segments: biotechnology, which develops products and services for therapeutic development including bioprocessing solutions, plasmid DNA, mRNA, proteins, and genomic medicines via brands such as Cytiva, Aldevron, and Abcam; life sciences, offering instruments like mass spectrometers, flow cytometry systems, microscopes, genomics consumables, lab automation, centrifugation, particle characterization, and gene and cell therapy tools; and diagnostics, providing clinical instruments, reagents, consumables, software, and services for disease diagnosis in hospitals, physicians' offices, reference laboratories, and critical care settings through subsidiaries including Cepheid and Beckman Coulter. Danaher serves customers worldwide across biopharmaceutical, research, healthcare, and precision medicine markets, employing approximately 63,000 associates in over 125 countries. Recent developments include the 2023 acquisition of Abcam for proteomic research consumables to accelerate drug discovery; a January 2025 investment partnership with Innovaccer Inc. through Danaher Diagnostics LLC and Danaher Ventures LLC to advance AI-enabled diagnostics and precision medicine; and a May 2025 diagnostic development and commercialization alliance with AstraZeneca to scale next-generation AI-powered diagnostics solutions.
Bank of Nova Scotia Sells 3,275 Shares of Danaher Corporation $DHR
Here's Why the Slump in Danaher Stock This Week Looks Like a Buying Opportunity
Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect?
Don't Quit on Danaher Stock After Horrific Earnings Reaction
Danaher Corporation $DHR Stake Raised by Andra AP fonden
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
Danaher Q2 Earnings Review: Nothing Exciting For Me To Buy This Dip
Danaher Corporation (DHR) Q2 2026 Earnings Call Transcript
Compared to Estimates, Danaher (DHR) Q2 Earnings: A Look at Key Metrics
Danaher Q2 Earnings Call Highlights
Danaher Plummets After One Segment Comes In 'Surprisingly Soft'
5 Things to Know Before the Stock Market Opens on Tuesday
Danaher's revenue outlook cut, biotech miss overshadow profit forecast raise
Danaher (DHR) Q2 Earnings and Revenues Top Estimates
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Danaher Reports Second Quarter 2026 Results
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Danaher Corporation $DHR Shares Acquired by Broderick Brian C
Allspring Global Investments Holdings LLC Decreases Stake in Danaher Corporation $DHR
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?